



For more information, contact:

Craig P. Niedenthal
Shareholder
Phone: 205.328.2200
Fax: 205.324.7896
E-mail: cniedenthal@cwcd.com

FOR IMMEDIATE RELEASE

**Cory Watson Crowder & DeGaris Files Lawsuit against
Pharmaceutical Giant Bayer AG**

78-year-old plaintiff seeks damages to cover medical costs, pain, suffering and kidney dialysis stemming from the use of Bayer drug Trasylo^l®

BIRMINGHAM, Ala., Feb. 19, 2007—Cory Watson Crowder & DeGaris, P.C. (www.cwcd.com), announced that it has filed a complaint against Bayer Corporation and its parent company, Bayer AG (NYSE:BAY) on behalf of plaintiff Ada M. Williams. Ms. Williams allegedly suffered permanent kidney damage after being given Trasylo^l®—a Bayer-manufactured drug given to patients during open-heart surgery to prevent the potential for excessive bleeding as a result of the surgery.

The lawsuit states that, as a result of being given Trasylo^l during open-heart surgery, Ms. Williams went into kidney failure and is now required to undergo kidney dialysis three days a week for the rest of her life. In the suit, Ms. Williams asks that a jury fairly compensate her for the pain and suffering her injury has created and for reimbursement of the added medical expenses she continues to incur. The suit was filed Jan. 25, 2007, in the United States District Court for the Middle District of Tennessee, Columbia Division (Case 1:07-cv-00004). Cory Watson Crowder & DeGaris is one of the first law firms in the nation to bring suit against Bayer Corporation regarding Trasylo^l.

-MORE-

“Ms. Williams is being forced to live the rest of her life with severe and life-threatening kidney problems,” says Craig P. Niedenthal, shareholder at Cory Watson Crowder & DeGaris. Mr. Niedenthal and the law firm of Cory Watson Crowder & DeGaris are currently reviewing additional potential Trayslol claims.

Earlier this month, the results of an observational study looking at the long-term effects to patients given Trayslol during open-heart surgery was published in the *Journal of the American Medical Association*. The doctors who published the study concluded that Trayslol use during open-heart surgery is associated with an increased risk of death during the first five years after the surgery. The article also estimated that if other, cheaper medications were used instead of Trayslol, approximately 2,000 deaths per year might be avoided.

Additionally, a study published in *The New England Journal of Medicine* in January 2006 revealed that Trasyolol doubled the risk of kidney failure in patients given Trasyolol during open-heart surgery. In contrast, the study noted two generic drugs that cost significantly less than Trasyolol and perform the same function during the surgery produced no increased risk of kidney failure.

About Cory Watson Crowder & DeGaris P.C.

Based in Birmingham, Alabama, Cory Watson Crowder & DeGaris was founded in 1995, and is recognized as one of the region’s leading law firms committed entirely to representing individuals and businesses harmed by the wrongful conduct of others. The largest area of the firm’s practice is products liability, including litigation of defective consumer and household goods, motor vehicles, medical devices and pharmaceuticals. The shareholders have litigated product liability cases across the country, in state and federal courts, and have received numerous appointments to litigation steering committees and discovery committees in multi-district litigation product liability proceedings. The firm has been at the forefront of protecting people harmed by the actions of pharmaceutical companies and has recovered more than \$500 million in settlements and verdicts for its clients.

###